Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes
Curcumin Supplementation and Type 2 Diabetes
1 other identifier
interventional
50
1 country
1
Brief Summary
Diabetes mellitus is the most common endocrine disorder, causes many complications such as micro- and macro-vascular diseases. Various kinds of antidiabetic drugs have been developed, but most of them have side effects. Recently, the use of natural plant products has gained more attention among scientists in order to prevent diabetic vascular complications. Curcumin is a natural yellow product derived from the turmeric rhizome which has shown to be non-toxic and exhibits various bio¬logical activities such as anti-oxidant, anti-inflammatory, anti-carcinogenic, and anti-diabetic effects. Curcumin is effective in reducing glycemic index and hyperlipidemia in rodent models and is relatively inexpensive and safe. Most of the studies conducted on animal model, and just a few of them are on human model. The present study was planned to evaluate the effects of curcumin supplementation on serum levels of lipid profile and inflammatory markers in patients with type 2 diabetes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2015
CompletedFirst Submitted
Initial submission to the registry
August 19, 2015
CompletedFirst Posted
Study publicly available on registry
August 20, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2016
CompletedAugust 20, 2015
July 1, 2015
6 months
August 19, 2015
August 19, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Triglyceride
12 weeks
Secondary Outcomes (1)
C-Reactive Protein
12 weeks
Study Arms (2)
intervention
ACTIVE COMPARATOR500 mg curcumin capsule
placebo
PLACEBO COMPARATOR500 mg placebo
Interventions
Eligibility Criteria
You may qualify if:
- Tendency to participate
- Age range of 40-65
- Suffering from diabetes type 2 ( between 1 to 10 yeares)
- BMI 18/5-30
- Patients with diabetes who administer oral hypoglycemic agents and do not use
You may not qualify if:
- patients with liver diseases
- patients with kidney diseases
- patients with inflammatory diseases
- patients with liver diseases
- Administering herbal agents
- Administering multivitamins and minerals in past 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
NNFTRI clinic
Tehran, Tehran Province, 19435, Iran
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 19, 2015
First Posted
August 20, 2015
Study Start
July 1, 2015
Primary Completion
January 1, 2016
Last Updated
August 20, 2015
Record last verified: 2015-07